Outset Medical (OM) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
24 Apr, 2026Voting matters and shareholder proposals
Election of two Class III directors: Brent D. Lang and Karen Prange, with board recommendation to vote for both nominees.
Advisory vote to approve 2025 compensation for named executive officers, recommended for approval by the board.
Ratification of KPMG LLP as independent registered public accounting firm for fiscal year 2026, with board recommendation to vote for.
Proxy holders authorized to vote on other business that may arise at the meeting or any adjournment.
Board of directors and corporate governance
Board is presenting two nominees for election to Class III director positions at the annual meeting.
Executive compensation and say-on-pay
Shareholders are asked to approve, on a non-binding basis, the 2025 compensation for named executive officers.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Outset Medical
- Q2 2026 revenue grew 1% to $31.6M, gross margin reached 42.2%, and a $40M HCA deal boosts outlook.OM
Q2 2026 - All proposals passed, with directors elected and auditor ratified; no questions from stockholders.OM
AGM 2026 - Next-gen Tablo launch and console refresh cycle set to drive growth and profitability in 2026.OM
RBC Capital Markets Global Healthcare Conference 2026 - Q1 revenue fell 6% but gross margin hit 43.4% and net loss narrowed to $19.0 million.OM
Q1 2026 - Annual meeting covers director elections, say-on-pay, auditor ratification, and governance updates.OM
Proxy filing - 2025 revenue up 5%, gross margin expands, net loss narrows, and FDA clearance drives 2026 growth.OM
Q4 2025 - Revenue declined but gross margin and recurring revenue improved; 2024 outlook lowered.OM
Q2 2024 - Cost reductions and margin expansion accelerate profitability as TabloCart ramps post-clearance.OM
Goldman Sachs 45th Annual Global Healthcare Conference - Q1 2025 revenue up 6% to $29.8M, gross margin and liquidity improved, net loss narrowed.OM
Q1 2025